Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in ABL kinase domain are associated with inferior progression-free survival.

Leukemia & lymphoma - 1 Jun 2010

Sharma Pratibha, Mohanty Sujata, Kochupillai Vinod, Kumar Lalit

Abstract excerpt

Imatinib mesylate is currently the drug of choice for all phases of chronic myeloid leukemia (CML). Despite the initial high rates of hematological and cytogenetic responses, many patients develop resistance. We prospectively studied 40 patients with CML with primary cytogenetic resistance to imatinib mesylate. A semi-nested reverse transcriptase-PCR approach was used for amplification of the ABL kinase domain,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Disease-Free Survival
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Proto-Oncogene Proteins c-abl

Share to Pyrimidines

Source

Identifiers

PMID: 20367437
DOI: 10.3109/10428191003729741

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in ABL kinase domain are associated with inferior progression-free survival.PMID 20367437Read ↗

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.Semantic proximity Read ↗

Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.Semantic proximity Read ↗

Detection of BCR-ABL mutations and resistance to imatinib mesylate.Semantic proximity Read ↗

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.Semantic proximity Read ↗

Resistance to imatinib: mutations and beyond.Semantic proximity Read ↗

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read ↗

Resistance to targeted therapy in chronic myelogenous leukemia.Semantic proximity Read ↗

Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.Semantic proximity Read ↗

Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?Semantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.